Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MD-Gastroview vs Omnipaque for Adhesive Small Bowel Obstruction
NCT02928458Withdrawn
- Sponsor
- Guthrie
- Start
- Sep 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in Adhesive small bowel obstruction (ASBO) comparing Omnipaque with MD-Gastroview (2 arms). Primary endpoint: Average Length of Stay at 3 years. Planned start Sep 2015; status: withdrawn.
02
Drugs
diatrizoate meglumineiohexol
03
Conditions
Adhesive small bowel obstruction (ASBO)
Beyond the preview
Go deeper on NCT02928458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928458.